Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease: Prospective 5 Years of Follow-Up and Apolipoprotein(a) Characterization

Cited by (226)

Items 101–200 of 226

1. Lipoprotein(a) apheresis in patients with peripheral arterial disease: rationale and clinical results
   Norbert Weiss, Ulrich Julius · 2019 · Clinical Research in Cardiology Supplements
2. Therapeutic management of hyperlipoproteinemia (a)
   Constantine E. Kosmas, Andreas Sourlas, Gordon Mallarkey, Delia Silverio, Domingo Ynoa Garcia, Peter D. Montan, Eliscer Guzman, Mario Jorge Garcia · 2019 · Drugs in Context
3. Lipoprotein(a) in clinical practice: A guide for the clinician
   Chayakrit Krittanawong, Neil Sagar Maitra, Adham El Sherbini, Nishant R. Shah, Carl J. Lavie, Michael David Shapiro, Salim S. Virani · 2023 · Progress in Cardiovascular Diseases
4. Real‐world study: Escalating targeted lipid‐lowering treatment with PCSK9‐inhibitors and lipoprotein apheresis
   Ralf Spitthöver, Tilmann Röseler, Ulrich Julius, Franz Heigl, Volker J. J. Schettler, Ralf Kühn, Josef Leebmann, Andrea Raabe, Markus Knittel, Carsten Schürfeld et al. · 2019 · Journal of Clinical Apheresis
5. Lipoprotein(a)—antisense therapy
   Anja Vogt · 2019 · Clinical Research in Cardiology Supplements
6. Identification and analyses of inhibitors targeting apolipoprotein(a) kringle domains KIV-7, KIV-10, and KV provide insight into kringle domain function
   Jenny Sandmark, Anna Tigerström, Tomas Åkerud, Magnus Althage, Thomas Antonsson, Stefan Blaho, Cristian Bodin, Jonas Boström, Yantao Chen, Anders Dahlén et al. · 2020 · Journal of Biological Chemistry
7. Lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 inhibitors
   Ulrich Julius, S. Tselmin, Ulrike Schatz, Sabine Fischer, Stefan Richard Bornstein · 2019 · Clinical Research in Cardiology Supplements
8. Lipoprotein (a) as a treatment target for cardiovascular disease prevention and related therapeutic strategies: a critical overview
   Ioannis Parthymos, Michael S. Kostapanos, Dimitri P. Mikhailidis, Matilda Florentin · 2021 · European Journal of Preventive Cardiology
9. Multimodal lipid-lowering treatment in pediatric patients with homozygous familial hypercholesterolemia—target attainment requires further increase of intensity
   Günter Klaus, Christina Taylan, Rainer Büscher, Claus Peter Schmitt, Lars Pape, Jun Seok Oh, Joenna Driemeyer, Matthias Galiano, Jens Christian König, Carsten Schürfeld et al. · 2018 · Pediatric Nephrology
10. LP(a): The new marker of high cardiovascular risk
    Maurizio Rocco Averna, Angelo Baldassare Cefalu · 2024 · Nutrition Metabolism and Cardiovascular Diseases
11. Emerging Therapeutic Options for Lowering of Lipoprotein(a): Implications for Prevention of Cardiovascular Disease
    Michael B. Boffa · 2016 · Current Atherosclerosis Reports
12. Is Lipoprotein(a) Ready for Prime-Time Use in the Clinic?
    Katrina L. Ellis, Gerald Francis Watts · 2018 · Cardiology Clinics
13. Lipoprotein (a) and Low‐density lipoprotein apolipoprotein B metabolism following apheresis in patients with elevated lipoprotein(a) and coronary artery disease
    Louis Ma, Elisa Waldmann, Esther M. M. Ooi, Dick C. Chan, P. Hugh R. Barrett, Gerald Francis Watts, Klaus Georg Parhofer · 2018 · European Journal of Clinical Investigation
14. Genetics of Lipoprotein(a): Cardiovascular Disease and Future Therapy
    Anne Langsted, Børge Grønne Nordestgaard · 2021 · Current Atherosclerosis Reports
15. Beyond cholesterol—pleiotropic effects of lipoprotein apheresis
    Volker J. J. Schettler, Elke Schettler · 2022 · Therapeutic Apheresis and Dialysis
16. Lipoprotein(a): cardiovascular risk and emerging therapies
    Masashi Fujino, Stephen James Nicholls · 2023 · Expert Review of Cardiovascular Therapy
17. Lipoprotein(a)-apheresis in the light of new drug developments
    Anja Vogt · 2017 · Atherosclerosis Supplements
18. The journey towards understanding lipoprotein(a) and cardiovascular disease risk: are we there yet?
    Michael B. Boffa, Marlys L. Koschinsky · 2018 · Current Opinion in Lipidology
19. Lipoprotein apheresis in Germany – Still more commonly indicated than implemented. How can patients in need access therapy?
    Franz Heigl, Tobias Pflederer, Reinhard Klingel, Reinhard Hettich, Norbert Lotz, Harduin Reeg, Volker J. J. Schettler, Eberhard Roeseler, Peter Grützmacher, Bernd Hohenstein et al. · 2019 · Atherosclerosis Supplements
20. ODYSSEY ESCAPE: is PCSK9 inhibition the Trojan Horse for the use of lipoprotein apheresis in familial hypercholesterolaemia?
    Gerald Francis Watts, Claudia Stefanutti · 2016 · European Heart Journal
21. Increased cardiovascular risk associated to hyperlipoproteinemia (a) and the challenges of current and future therapeutic possibilities
    Zlatko Fras · 2019 · The Anatolian Journal of Cardiology
22. Factorial Mendelian randomization of lipoprotein (a) lowering, low-density lipoprotein cholesterol lowering, and lifestyle improvements: joint associations with cardiovascular risk
    Lijuan Wang, Fangyuan Jiang, Jing Sun, Jianhui Zhao, Yazhou He, Dipender Gill, Stephen Burgess, Susanna C. Larsson, Shuai Yuan, Xue Li · 2025 · International Journal of Epidemiology
23. Lipoprotein (a) as a Marker for Predicting the Presence and Severity of Coronary Artery Disease in Untreated Chinese Patients Undergoing Coronary Angiography.
    Di Sun, Xi Zhao, Sha Li, Yan Zhang, Na Qiong Wu, Cheng Gang Zhu, Yuan Lin Guo, Ying Gao, Ping Qing, Geng Liu et al. · 2018 · PubMed
24. Lipoprotein(a): Its Association with Calcific Aortic Valve Stenosis, the Emerging RNA-Related Treatments and the Hope for a New Era in “Treating” Aortic Valve Calcification
    Donatos Tsamoulis, Iliana Siountri, Lοukianos S. Rallidis · 2023 · Journal of Cardiovascular Development and Disease
25. Lipoprotein(a) – Marker for cardiovascular risk and target for lipoprotein apheresis
    Reinhard Klingel, Franz Heigl, Volker J. J. Schettler, Eberhard Roeseler, Peter Grützmacher, Bernd Hohenstein, Anja Vogt, Cordula Fassbender, Andreas Heibges, Ulrich Julius · 2019 · Atherosclerosis Supplements
26. Why Some Patients Undergoing Lipoprotein Apheresis Therapy Develop New Cardiovascular Events?
    Ulrich Julius, Solveig Kuss, Sergey Tselmin, Ulrike Schatz, Stefan Richard Bornstein · 2020 · Journal of Cardiovascular Development and Disease
27. The Riskier Lipid: What Is on the HORIZON for Lipoprotein (a) and Should There Be Lp(a) Screening for All?
    Stephen James Nicholls, Kristen J. Bubb · 2021 · Current Cardiology Reports
28. Elusive Therapeutic Effect of PCSK9 Inhibitors on Lipoprotein(a) Levels
    Francesco Sbrana, Federico Bigazzi, Beatrice Dal Pino, Maddalena Toma, Andrea Ripoli, Tiziana Sampietro · 2018 · Therapeutic Apheresis and Dialysis
29. Lipoprotein(a)-lowering therapies: a promising future
    Jingwen Zhang, Ann Marie Návar, Lale S Tokgözoğlu · 2026 · European Heart Journal
30. How effectively will PCSK9 inhibitors allow retrieval of freedom from apheresis in cardiovascular high risk patients? – Estimates form a large single center
    Bernd Hohenstein, Sergey Tselmin, Stefan Richard Bornstein, Ulrich Julius · 2017 · Atherosclerosis Supplements
31. Lipoprotein(a) in Patients With Type 2 Diabetes and Premature Coronary Artery Disease in the Coronary Care Unit
    Nick S.R. Lan, Dick C. Chan, Jing Pang, P. Gerry Fegan, Bu Beng Yeap, James M. Rankin, Carl Johann Schultz, Gerald Francis Watts, Damon A. Bell · 2020 · Heart Lung and Circulation
32. Pharmacotherapy for children with elevated levels of lipoprotein(a): future directions
    Lotte M. de Boer, Albert Wiegman, Daniel I. Swerdlow, John J.P. Kastelein, Barbara A. Hutten · 2022 · Expert Opinion on Pharmacotherapy
33. Lipoprotein(a) and Atherosclerotic Cardiovascular Disease, the Impact of Available Lipid-Lowering Medications on Lipoprotein(a): An Update on New Therapies
    Takahiro Tsushima, Yumiko Tsushima, Claire Sullivan, Betül Hatipoğlu · 2022 · Endocrine Practice
34. Will you, nill you, I will treat you: the taming of lipoprotein(a)
    Arnold von Eckardstein · 2017 · European Heart Journal
35. Lipoprotein apheresis for lipoprotein(a)-associated progressive atherosclerotic cardiovascular disease: 12-years follow-up
    Reinhard Klingel, Ulrich Julius, Wanja M. Bernhardt, Franz Heigl, Ralf Spitthöver, Josef Leebmann, Volker J. J. Schettler, Walter Lehmacher, Børge Grønne Nordestgaard, Florian Kronenberg et al. · 2025 · Atherosclerosis
36. Pelacarsen and lipoprotein(a) apheresis in secondary prevention: the Lp(a)FRONTIERS APHERESIS trial
    Klaus G. Parhofer, Ulrich Julius, Anna Laura Herzog, Thilo Krüger, Julia Weinmann‐Menke, Gunnar Henrik Heine, Hui Cao, Jessica Schorr, Philippe C. Ferber, Jing Wang et al. · 2026 · European Heart Journal
37. Lipoprotein(a): lodestar for future clinical trials
    Gerald Francis Watts, Michael B. Boffa · 2018 · The Lancet
38. All we need to know about lipoprotein(a)
    Courtney Bess, Anurag Mehta, Parag H. Joshi · 2024 · Progress in Cardiovascular Diseases
39. Hyperlipoproteinaemia(a) – apheresis and emerging therapies
    Anja Vogt · 2017 · Clinical Research in Cardiology Supplements
40. Kinetics of Lipoprotein(a) in patients undergoing weekly lipoprotein apheresis for Lp(a) hyperlipoproteinemia
    S. Tselmin, Gabriele Müller, Ulrike Schatz, Ulrich Julius, Stefan Richard Bornstein, Bernd Hohenstein · 2017 · Atherosclerosis Supplements
41. Statins—Their Effect on Lipoprotein(a) Levels
    Marcin Mateusz Granat · 2025 · Reviews in Cardiovascular Medicine
42. Peripheral arterial disease associated with elevated lipoprotein(a): a review of the evidence and treatment approaches
    Harpreet Singh Bhatia, Sonar Dalal, Elsie Ross · 2025 · Current Opinion in Lipidology
43. Lipoprotein (a) in primary cardiovascular disease prevention is actionable today
    Vibhu Parcha, Vera Bittner · 2025 · American Heart Journal Plus Cardiology Research and Practice
44. Recent Advances in the Genetics of Atherothrombotic Disease and Its Determinants
    Jacqueline S. Dron, Rosettia Ho, Robert Alexander Hegele · 2017 · Arteriosclerosis Thrombosis and Vascular Biology
45. Lipoprotein apheresis in Austria – Reduction of cardiovascular events by regular lipoprotein apheresis treatment
    Theresa Berent, Kurt Derfler, Robert Berent, Helmut F. Sinzinger · 2019 · Atherosclerosis Supplements
46. Cardiovascular events in patients with familial hypercholesterolemia and hyperlipoproteinaemia (a): Indications for lipoprotein apheresis in Poland
    Agnieszka Mickiewicz, Joanna Marlęga-Linert, Agnieszka Kuchta, Witold Bachorski, Agnieszka Ćwiklińska, Grzegorz Raczak, Marcin Gruchała, Marcin Fijałkowski · 2021 · Journal of Clinical Apheresis
47. Association of free-living diet composition with plasma lipoprotein(a) levels in healthy adults
    Anastasiya Matveyenko, Heather Seid, Kyungyeon Kim, Nelsa Matienzo, Rajasekhar Ramakrishnan, Tiffany Thomas, Gissette Reyes‐Soffer · 2023 · Lipids in Health and Disease
48. Relationship between Lipoprotein(a) and cardiovascular risk factors—data from 4602 participants of the ELITE study
    Bastian Schrader, Abdul Shakoor, Annika Schmidt, Joachim Schrader, Bernhard Vaske, Hermann G. Haller, Michael Johann Koziolek, Albrecht Elsässer, Stephan Lüders · 2021 · Reviews in Cardiovascular Medicine
49. Current insights into the German lipoprotein apheresis standard: PCSK9-inhibitors, lipoprotein apheresis or both?
    Volker J. J. Schettler, Jens Ringel, S. Jacob, Ulrich Julius, Reinhard Klingel, Franz Heigl, Eberhard Roeseler, Peter Grützmacher · 2017 · Atherosclerosis Supplements
50. Strategies for management of patients with elevated lipoprotein(a)
    Charlotte C Ellberg, Harpreet Singh Bhatia · 2024 · Current Opinion in Lipidology
51. Coronary Plaque Characteristics Assessed by Optical Coherence Tomography and Plasma Lipoprotein(a) Levels in Patients With Acute Coronary Syndrome
    Francesca Maria Di Muro, Maria Federica Crociani, Giulia Nardi, Niccolò Ciardetti, Lucrezia Biagiotti, Elisa Bigi, Francesco Meucci, Miroslava Stolcova, Francesca Ristalli, Emanuele Cecchi et al. · 2024 · Catheterization and Cardiovascular Interventions
52. State of the Art: Lipoproteinapherese
    Ulrike Schatz, Volker J. J. Schettler, Ulrich Julius · 2023 · DMW - Deutsche Medizinische Wochenschrift
53. Primary and secondary prevention of cardiovascular disease in patients with hyperlipoproteinemia (a)
    Peter Grützmacher, Brigitte Öhm, Steffi Szymczak, Christian Dorbath, Martin Brzoska, Claudius Kleinert · 2017 · Clinical Research in Cardiology Supplements
54. In Search of Patients With Elevated Lp(a)
    Sotirios Tsimikas · 2019 · Journal of the American College of Cardiology
55. Lipoprotein(a) – treatments in development
    Brian Tomlinson, C. Law · 2025 · Expert Opinion on Pharmacotherapy
56. Efficacy of Traditional Anti-lipidemic Drugs in Lowering Lipoprotein(a) Levels: A Systematic Review
    Mohit Sinha, Rafik Maged, Pakeeza Tarar, Venkata Varshitha Bandi, Hema Manvi Koneru, Hooria Sarwar · 2024 · Cureus
57. Lipoprotein(a) Testing and Emerging Therapies
    Perry Mayo-Malasky, William H. Frishman · 2019 · Cardiology in Review
58. Lipoprotein (a) in familial hypercholesterolaemia
    Paul N. Durrington, Bilal Bashir, Deepak Bhatnagar, Handrean Soran · 2022 · Current Opinion in Lipidology
59. Is Lipoprotein(a) Clinically Actionable with Today’s Evidence? The Answer is Yes
    Gary S. Ma, Tommy T. Chiou, Michael J. Wilkinson · 2023 · Current Cardiology Reports
60. Homozygous familial hypercholesterolemia with severe involvement of the aortic valve—A sibling‐controlled case study on the efficacy of lipoprotein apheresis
    Matthias Galiano, Johanna E Hammersen, Katja Sauerstein, Holger Blessing, Petra Rümmele, Ariawan Purbojo, Martin Schöber, Julia Moosmann, Gunter Raffelsbauer, Andreas Heibges et al. · 2020 · Journal of Clinical Apheresis
61. Comparison of plasma separation using centrifugation or filtration for MONET lipoprotein apheresis in patients with cardiovascular disease and severe dyslipidemia
    Grit Waitz, Saynab Atiye, Adelheid Gauly, Heinrich Prophet · 2022 · Therapeutic Apheresis and Dialysis
62. Why continued lipoprotein apheresis is vital for homozygous familial hypercholesterolemia patients with COVID-19
    Alpo F. Vuorio, Frederick Johan Raal, Reinhard Klingel, Petri T. Kovanen · 2021 · Journal of clinical lipidology
63. The evolution of lipid-lowering drugs in the management of cardiovascular disease risk: From the first cardiovascular disease risk–reducing therapies to the novel challenging strategies
    Doriane Henry, Eric Baugé, Bart Staels, Fanny Lalloyer · 2025 · Pharmacological Reviews
64. Oral agents for lowering lipoprotein(a)
    Stephen James Nicholls, Adam J. Nelson, Laura F. Michael · 2024 · Current Opinion in Lipidology
65. Lipoprotein(a) in atherosclerotic cardiovascular disease and proprotein convertase subtilisin/kexin-type 9 inhibitors
    Pingan Lian, Wen-qiang Zhu, Wei-xin Zhao, Piaopiao Huang, Juanli Ran, Yaxin Tang, Xiansheng Huang, Rong Li · 2024 · Clinica Chimica Acta
66. The impact of lipid apheresis on changes of lipoprotein(a): a systematic review and meta-analysis
    Bahman Razi, Masoud Eslami, Saeed Aslani, Shahab Alizadeh, Alireza Hatami, Wael A. Almahmeed, Salim S. Virani, Amirhossein Sahebkar · 2026 · European Journal of Preventive Cardiology
67. Lipoprotein(a) as a Predictive Biomarker and Therapeutic Target for Acute Coronary Syndromes
    Yannis Dimitroglou, Constantina Aggeli, Panagiotis Theofilis, Panagiotis Tsioufis, Evangelos K. Oikonomou, Konstantinos P Tsioufis, Dimitris Tousoulis · 2023 · Current Pharmaceutical Design
68. To test, or not to test: that is the question for the future of lipoprotein(a)
    Katrina L. Ellis, Anindita Chakraborty, Eric Keith Moses, Gerald Francis Watts · 2019 · Expert Review of Cardiovascular Therapy
69. Experience with proprotein convertase subtilisin/kexine type 9 inhibitors (PCSK9i) in patients undergoing lipoprotein apheresis
    Sergey Tselmin, Ulrich Julius, Nadine Weinert, Stefan Richard Bornstein, Ulrike Schatz · 2019 · Atherosclerosis Supplements
70. Recent Highlights of ATVB
    Jacqueline S. Dron, Julieta Lazarte, Robert Alexander Hegele · 2018 · Arteriosclerosis Thrombosis and Vascular Biology
71. Lipoprotein(a) - the cardiovascular risk factor: significance and therapeutic possibilities
    Vladimir Blaha · 2018 · Vnitřní lékařství
72. Lipoprotein(a)—When to Screen and How to Treat
    Neeja Patel, Nikita Mittal, Parnia Abolhassan Choubdar, Pam R. Taub · 2022 · Current Cardiovascular Risk Reports
73. Alirocumab in lipoprotein apheresis: A synergy for patients with high-Lp(a)
    Francesco Sbrana, Federico Bigazzi, Andrea Ripoli, Beatrice Dal Pino · 2023 · Transfusion and Apheresis Science
74. New and Emerging Therapies for Dyslipidemia
    Alberto Zambon, Maurizio Rocco Averna, Laura D’Erasmo, Marcello Arca, Alberico Luigi Catapano · 2022 · Endocrinology and Metabolism Clinics of North America
75. Lipoprotein(a) Lowering with Pelacarsen (TQJ230)
    Kunal Sharma, Lakshmi Prasanna Vaishnavi Kattamuri, Debabrata Mukherjee · 2025 · Cardiovascular & Haematological Disorders - Drug Targets
76. Is it possible to regress atherosclerotic lesions with long-term treatment with lipoprotein apheresis?
    Ulrich Julius, Sergey Tselmin, Viktoria A. Korneva · 2024 · Russian Journal of Cardiology
77. The time for lipoprotein(a) based intervention has arrived: where will the light shine?
    Stephen James Nicholls, Adam J. Nelson · 2019 · Journal of Thoracic Disease
78. Lipoprotein(a) Elevation: A New Diagnostic Code with Relevance to Service Members and Veterans.
    Renata J.M. Engler, Emily Brede, Todd C. Villines, Marina Vernalis · 2019 · PubMed Central
79. Combined Treatment With Lipoprotein Apheresis and Hemodialysis in Patients With Severe Cardiovascular Disease, High Lipoprotein(a) and End Stage Renal Disease
    Tilmann Röseler, Daniel Kayser, Georg Schlieper, Wanja M. Bernhardt · 2025 · Journal of Clinical Apheresis
80. Impact of Lipoprotein(a) on Residual Cardiovascular Risk After an Acute Coronary Syndrome
    Nelsa González-Aguado, Rafael Franco-Hita, Jose Ignacio Larrubia-Valle, Fernando Puyol-Ruiz, Ainhoa Robles Mezcua, José Manuel García‐Pinilla, María Jiménez-Salva, Alberto Piserra‐López, Francisco Javier Pavón, Alejandro Pérez-Cabeza et al. · 2026 · Journal of Clinical Medicine
81. The association of MASLD, lipoprotein(a) and long-term outcomes: Results from the multi-ethnic study of atherosclerosis
    Gomathy Nageswaran, Vignesh Chidambaram, Amudha Kumar, Rami Doukky, Thorsten Martin Leucker, Subhi Al'Aref, Ragesh B. Thandassery · 2026 · Metabolism
82. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice—Evidence‐Based Approach From the Writing Committee of the American Society for Apheresis: The Tenth Special Issue
    Nicole D. Zantek, Caroline Raasch Alquist, Jan C. Hofmann, Reinhard Klingel, Yosef Levenbrown, Oluwatoyosi A. Onwuemene, Gopal Kumar Patidar, Christopher Jordan Patriquin, Jay S. Raval, Amber P. Sanchez et al. · 2026 · Journal of Clinical Apheresis
83. Frequency & factors associated with elevated lipoprotein-a among Ghanaian stroke survivors
    Solomon Gyabaah, Yaw Adu‐Boakye, Osei Sarfo‐Kantanka, Kwadwo Faka Gyan, Collins Kokuro, Martin Kofi Agyei, John Akassi, Phyllis Tawiah, Betty Norman, Bruce I Ovbiagele et al. · 2023 · Journal of the Neurological Sciences
84. Lipoprotein(a)-hyperlipoproteinemia as cause of chronic spinal cord ischemia resulting in progressive myelopathy – successful treatment with lipoprotein apheresis
    Franz Heigl, Reinhard Hettich, Erich Mauch, Reinhard Klingel, Cordula Fassbender · 2017 · Clinical Research in Cardiology Supplements
85. Lipoprotein(a)—an interdisciplinary challenge
    Ulrich Julius, S. Tselmin, Ulrike Schatz, Sabine Fischer, Stefan Richard Bornstein · 2019 · Clinical Research in Cardiology Supplements
86. Clinical practice recommendations on lipoprotein apheresis for children with homozygous familial hypercholesterolemia: an expert consensus statement from ERKNet and ESPN
    M. Doortje Reijman, D. Meeike Kusters, Jaap W. Groothoff, Klaus Arbeiter, Eldad J. Dann, Lotte M. de Boer, Sarah D. de Ferranti, Antonio Gallo, Susanne Greber‐Platzer, Jacob Hartz et al. · 2023 · medRxiv
87. Lipoprotein(a) as a Predictor of Nonalcoholic Fatty Liver After Pancreatectomy
    Kyohei Abe, SHUICHI FUJIOKA, Yuki Takano, Yoshihiro Shirai, Masashi Tsunematsu, Michinori Matsumoto, Kenei Furukawa, Koichiro Haruki, Shinji Onda, Toru Ikegami · 2024 · Anticancer Research
88. Lipoproteina(a) e rischio cardiovascolare: una roadmap per la gestione del paziente. Documento congiunto della Società Italiana per lo studio dell'Aterosclerosi (SISA), della Società Italiana di Cardiologia (SIC), della Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO) e di SIBioC
    Alberico Luigi Catapano, Pasquale Perrone Filardi, Fabrizio Giovanni Oliva, Luisa Agnello, Andrea Baragetti, Martina Berteotti, Claudio Bilato, Paolo Calabrò, Arturo Cesaro, Anna Maria Gori et al. · 2025 · Biochimica Clinica
89. Lipoprotein(a) and cardiovascular risk: A roadmap for patient management
    Alberico Luigi Catapano, Pasquale Perrone Filardi, Fabrizio Giovanni Oliva, Luisa Agnello, Andrea Baragetti, Martina Berteotti, Claudio Bilato, Paolo Calabrò, Arturo Cesaro, Anna Maria Gori et al. · 2025 · European Atherosclerosis Journal
90. Lipoprotein(a) and calcific aortic stenosis: from inherited risk marker to therapeutic target
    Francisco Epelde · 2026 · Frontiers in Medicine
91. Lipoprotein(a) – es wird Zeit, das Dornröschen wach zu küssen
    Florian Kronenberg · 2017 · Praxis
92. LIPOPROTEIN APHERESIS: YESTERDAY, TODAY, TOMORROW. REVIEW
    Ulrich Julius, S. Tselmin, Stefan Richard Bornstein · 2018 · Russian Journal of Cardiology
93. Lipoprotein(a): Metabolism, Pathophysiology, and Impact on Diabetes Mellitus
    Karam Kostner, Gerhard Max Kostner · 2023 · Contemporary diabetes
94. Weekly journal scan: a new small-interfering RNA to fight a genetic cardiovascular risk factor
    Daniela Pedicino, Massimo Volpe · 2024 · European Heart Journal
95. Hematologic Disorders and Stroke
    Cheryl Bushnell · 2015 · Elsevier eBooks
96. Results of Therapy at a Lipid Clinic in Patients with Elevated Lipoprotein(a) levels
    Ulrich Julius, Katarina Winter, Sergey Tselmin, Ulrike Schatz, Norbert Weiss, Sabine Fischer · 2022
97. Progress trotz Lipoproteinapherese
    Ulrike Schatz, Sabine Fischer, Sergey Tselmin, Andreas L. Birkenfeld, Ulrich Julius, Stefan Richard Bornstein · 2019 · CardioVasc
98. Ein Fall für die Lipoprotein-Apherese
    Wanja M. Bernhardt, Tilmann Röseler · 2017 · CardioVasc
99. Recurrent Cardiac Events Driven by Prothrombotic Burden in a Patient Undergoing Lipoprotein Apheresis for High Lp(a) Levels
    Gabriele Cioni · 2017 · Annals of Clinical Endocrinology and Metabolism
100. Stellenwert der lipidsenkenden Therapie in der Sekundärprophylaxe bei KHK
     Annely Hinck, Udo P Sechtem · 2018 · Der Klinikarzt